6533b827fe1ef96bd128671b

RESEARCH PRODUCT

In vivo endomicroscopy improves detection of Barrett’s esophagus–related neoplasia: a multicenter international randomized controlled trial

Jose Antonio N. AlmarioKerry B. DunbarSharmila AnandasabapathyZhe ZhangUrsula SchellElizabeth A. MontgomeryAnirban MaitraRalf KiesslichGary W. FalkWilliam R. BruggeKevin E. WoodsMarcia I. CantoJohn R. Goldblum

subject

AdultMalemedicine.medical_specialtyEndoscopeEsophageal NeoplasmsBiopsySpectrum Analysis RamanArticlelaw.inventionBarrett EsophagusEsophagusRandomized controlled triallawBiopsyEndomicroscopyMedicineHumansRadiology Nuclear Medicine and imagingSingle-Blind MethodProspective StudiesAgedAged 80 and overMicroscopy Confocalmedicine.diagnostic_testbusiness.industryGastroenterologyReproducibility of ResultsMiddle Agedmedicine.diseaseImage EnhancementEndoscopyClinical trialBarrett's esophagusCurrent Procedural TerminologyFemaleRadiologyEsophagoscopybusinessPrecancerous ConditionsFollow-Up Studies

description

Background Confocal laser endomicroscopy (CLE) enables in vivo microscopic imaging of the GI tract mucosa. However, there are limited data on endoscope-based CLE (eCLE) for imaging Barrett's esophagus (BE). Objective To compare high-definition white-light endoscopy (HDWLE) alone with random biopsy (RB) and HDWLE + eCLE and targeted biopsy (TB) for diagnosis of BE neoplasia. Design Multicenter, randomized, controlled trial. Setting Academic medical centers. Patients Adult patients with BE undergoing routine surveillance or referred for early neoplasia. Intervention Patients were randomized to HDWLE + RB (group 1) or HDWLE + eCLE + TB (group 2). Real-time diagnoses and management plans were recorded after HDWLE in both groups and after eCLE in group 2. Blinded expert pathology diagnosis was the reference standard. Main Outcome Measurements Diagnostic yield, performance characteristics, clinical impact. Results A total of 192 patients with BE were studied. HDWLE + eCLE + TB led to a lower number of mucosal biopsies and higher diagnostic yield for neoplasia (34% vs 7%; P P  = .002) and would have obviated the need for any biopsy in 65% of patients. The addition of eCLE to HDWLE increased the sensitivity for neoplasia detection to 96% from 40% ( P  0001) without significant reduction in specificity. In vivo CLE changed the treatment plan in 36% of patients. Limitations Tertiary-care referral centers and expert endoscopists limit generalizability. Conclusion Real-time eCLE and TB after HDWLE can improve the diagnostic yield and accuracy for neoplasia and significantly impact in vivo decision making by altering the diagnosis and guiding therapy. (Clinical trial registration number: NCT01124214.)

10.1016/j.gie.2013.09.020https://europepmc.org/articles/PMC4668117/